Latest Sales Strategy News

MyEco Group Ltd reported an 8.6% rise in FY25 sales driven by strong growth in its global MyEco® product line and new UK retail partnerships, while navigating challenges in resin markets and US tariffs.

Botanix Pharmaceuticals reports robust early sales and expanding prescriber engagement for Sofdra™, its FDA-approved topical gel for excessive underarm sweating, signaling promising growth ahead.

The Calmer Co. International Limited has reported a striking 86% revenue jump to over AU$8 million in FY25, propelled by diversified sales channels and a strategic US expansion highlighted by new flavoured kava shots launched exclusively on Amazon USA.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Minbos Resources advances its Cabinda Phosphate Project with strong sales interest and a $36 million financing package, positioning itself as a key player in Angola's agricultural transformation.

Universal Biosensors reports solid growth in its wine testing segment and outlines plans for a capital raise alongside the upcoming AQUASCOUT water testing device launch.

Guzman y Gomez has unveiled an ambitious expansion and margin improvement plan at the 2025 Macquarie Australia Conference, reaffirming its FY25 guidance and spotlighting strong franchise growth and operational excellence.

MyEco Group has secured $1.6 million through unsecured convertible notes to support a strategic operational restructure aimed at reducing costs and scaling production. This capital raise complements existing cash reserves and aims to improve margins while minimising shareholder dilution.

US Masters Residential Property Group has amended its loan agreement with Global Atlantic, significantly lowering its Tangible Net Worth covenant to align with a strategic sales-driven reduction in debt.

XPON Technologies reported a modest 1% quarter-on-quarter revenue increase to $2.09 million in Q3 FY25, driven by a strong 87% recurring revenue base and a 75% gross margin. The company extended its convertible note maturity and is focused on recalibrating sales and accelerating AI innovation.

EOS is midway through a strategic turnaround, divesting non-core assets and strengthening its balance sheet while advancing cutting-edge counter-drone, high energy laser weapons, and space control technologies amid robust global demand.

Elixinol Wellness reported a 13.7% year-on-year revenue increase in Q1 FY25, despite a softer quarter compared to record Q4, with ecommerce momentum and strategic initiatives setting the stage for margin recovery and growth in H2.